Library / learning-module
Understanding drug discovery
Audience: patients-public, students-learners ยท Review state: published
From idea to medicine
Drug discovery is the long funnel from a biological idea to a medicine. Regulators describe the first stage as discovery and development: researchers identify a target, such as a protein involved in a disease, then find or design compounds that affect it, and optimize the promising ones.
Thousands of candidates enter the funnel; a small fraction reaches human testing, and roughly one in ten of those that do will reach approval.
The discovery stage
Modern discovery starts with understanding the disease mechanism, then screens libraries of compounds against the target, mines natural products, or designs molecules computationally. Hits are confirmed, then refined in rounds of chemistry to improve potency, selectivity and drug-like properties.
The criteria are demanding: a candidate must reach its target in the body, survive metabolism long enough to work, and avoid off-target effects that cause harm.
Before human testing
Preclinical research tests candidates in cells and animals to map safety and behavior in the body: how the compound is absorbed, distributed, metabolized and excreted, and at what doses toxicity appears.
Only when this package satisfies regulators does testing in people begin, through phased trials that escalate from safety in a few volunteers to effectiveness in thousands of patients.
Why it takes so long
A decade or more and enormous cost are the norm, and most of that is attrition: compounds fail late, after years of investment, because human biology surprises even careful preclinical work. Each failure teaches, and failed programs routinely seed later successes.
For a reader, the pipeline explains both the price of new drugs and the patience behind them: the medicine on a shelf is the survivor of a process designed to kill weak candidates early.
Limitations
Educational overview of the drug discovery process, not an assessment of any specific drug or company.